Good Distribution Practice (GDP): Issue of Theft
The wholesale distribution of medicinal products and active substances is an important activity. The quality and the integrity of medicinal products can be affected by a lack of adequate control. The quality, [...]
EU: First steps taken to diminish drug shortages
Regulators in the European Union (EU) have began taking the first steps reduce shortages of medicinal products. The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) recently published two [...]
Pharma Industry Awards 2019 Finalists
MIAS Pharma are delighted to announce that we have been shortlisted in the Pharma Industry Awards 2019 for the 'Pharma Contract Services of the Year' category. The Pharma Industry Awards were set [...]
Further guidance on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal
The Medicines & Healthcare products Regulatory Agency (MHRA) have released further guidance on the regulation of medicines, medical devices and clinical trials if there is no Brexit deal. In relation to medicines: [...]
Further guidance on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal
The Medicines & Healthcare products Regulatory Agency (MHRA) have released further guidance on the regulation of medicines, medical devices and clinical trials if there is no Brexit deal. In relation to medicines: [...]
Hard-Brexit: MHRA preparations and impact on clinical trials
With the appointment of Boris Johnson as Prime Minister, it is likely that the United Kingdom (UK) may leave the European Union (EU) on the 31st of October 2019 and without a [...]
Get Social